Last updated: August 2, 2026
Ciprofloxacin in 5% dextrose injection is a mature, multisource intravenous generic used mainly in hospitals. Its commercial value is driven by procurement price, supply reliability, container convenience, and institutional demand rather than patent exclusivity. The product has no meaningful current patent barrier, no biosimilar exposure, and limited standalone financial disclosure. Revenue is likely stable to declining in unit terms, with periodic price increases during shortages or supplier exits.
What is ciprofloxacin in dextrose 5% used for?
Ciprofloxacin in dextrose 5% is an intravenous premixed formulation of ciprofloxacin hydrochloride in a dextrose solution. Common presentations include 200 mg in 100 mL and 400 mg in 200 mL containers, although available strengths and container sizes vary by manufacturer.
The product is used for serious or complicated bacterial infections when intravenous fluoroquinolone therapy is clinically appropriate. Label indications have included infections caused by susceptible organisms involving the lower respiratory tract, urinary tract, skin and skin structures, bones and joints, intra-abdominal sites, and other organs. Use is limited by antimicrobial resistance, fluoroquinolone safety warnings, and the availability of alternative agents. [1]
The premixed dextrose container is commercially important because it reduces pharmacy compounding requirements. Hospitals can store, dispense, and administer a ready-to-use product without preparing ciprofloxacin in a separate diluent.
How large is the ciprofloxacin injection market?
No public source reports global or U.S. revenue specifically for ciprofloxacin in dextrose 5% plastic containers. Manufacturers generally report broader hospital injectables, generic pharmaceuticals, or sterile-injectable portfolios rather than individual NDC-level sales.
The addressable market is narrower than the total ciprofloxacin market because it excludes:
- Oral ciprofloxacin tablets and extended-release tablets
- Ciprofloxacin oral suspension
- Ophthalmic and otic formulations
- Ciprofloxacin products supplied in alternative diluents or container systems
- Hospital-compounded intravenous formulations
The U.S. market is a mature generic injectable category. Demand is concentrated in acute-care hospitals, integrated delivery networks, government facilities, wholesalers, and group purchasing organizations. Unit growth is constrained by antimicrobial stewardship and substitution by other intravenous antibiotics.
Principal demand drivers
| Demand driver |
Commercial effect |
| Hospital admissions with serious Gram-negative infections |
Supports baseline demand |
| Ready-to-use premixed bags |
Supports use over pharmacy-compounded presentations |
| Drug shortages affecting alternatives |
Can produce temporary volume and price increases |
| Antimicrobial stewardship |
Limits routine and prolonged fluoroquinolone use |
| Resistance to ciprofloxacin |
Reduces clinical utilization in some organisms and regions |
| Hospital purchasing contracts |
Compresses price and supplier margins |
| Production reliability |
Can matter more than nominal list price |
Ciprofloxacin injection remains relevant in hospitals, but it does not have the growth profile of newer specialty drugs or high-value oncology biologics.
Who manufactures ciprofloxacin in dextrose 5% plastic containers?
The U.S. market has historically included the branded Cipro I.V. product and multiple generic suppliers. Supplier participation can change because of manufacturing transfers, discontinued NDCs, contract changes, or sterile-injectable capacity constraints.
Potential suppliers and commercial channels have included:
- Bayer, historically associated with Cipro I.V.
- Hospira, now part of Pfizer
- Fresenius Kabi
- Sandoz and other generic injectable suppliers
- Contract manufacturers and hospital-focused generic companies
The applicable manufacturer must be determined by NDC, strength, container size, and current listing status. A product description alone does not identify a single commercial owner.
Competitive products
Ciprofloxacin injection competes clinically and commercially with several intravenous antibiotics:
| Competing therapy |
Competitive relationship |
| Levofloxacin injection |
Direct fluoroquinolone substitute in selected indications |
| Ceftriaxone injection |
Common alternative for several community-acquired infections |
| Cefepime injection |
Used for broader Gram-negative coverage |
| Piperacillin/tazobactam |
Competes in polymicrobial and hospital-acquired infections |
| Meropenem and other carbapenems |
Preferred in selected resistant infections |
| Oral ciprofloxacin |
Substitution option when patients can absorb oral therapy |
| Pharmacy-compounded ciprofloxacin |
Lower packaging cost but higher preparation burden |
The product’s clinical position depends on local susceptibility data, hospital guidelines, renal dosing requirements, and formulary policy.
What is the FDA regulatory status of ciprofloxacin in dextrose 5%?
Ciprofloxacin injection is an FDA-approved prescription drug. The branded Cipro I.V. product was approved under an NDA, while generic versions are generally approved through ANDAs demonstrating pharmaceutical equivalence and bioequivalence or applicable injectable-product requirements.
The original branded product was approved decades ago. Current commercial presentations can have different approval histories, NDC listings, labeling updates, and marketing status. FDA-approved labeling identifies ciprofloxacin injection as a prescription antibacterial product and includes boxed warnings concerning serious fluoroquinolone-associated risks. [1]
FDA regulatory characteristics
| Regulatory issue |
Status |
| Regulatory pathway |
Original NDA plus generic ANDAs |
| Prescription status |
Prescription-only |
| Reference product |
Cipro I.V. historical reference product |
| Therapeutic category |
Systemic antibacterial; fluoroquinolone |
| Biosimilar pathway |
Not applicable |
| Current market structure |
Multisource generic injectable |
| Exclusivity |
No meaningful current new-drug exclusivity |
| FDA shortage exposure |
Dependent on supplier and presentation; not a structural patent issue |
FDA labeling has emphasized risks including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, exacerbation of myasthenia gravis, and potentially serious adverse reactions. These warnings influence prescribing and can reduce demand in situations where a safer alternative is available. [1, 2]
What patents protect ciprofloxacin in dextrose 5%?
The original ciprofloxacin compound and branded product patents expired long ago. The active ingredient is therefore available to multiple generic manufacturers.
The main patent conclusions are:
- No current composition-of-matter patent protects ciprofloxacin.
- No active patent estate creates a meaningful U.S. exclusivity barrier for the basic intravenous product.
- The dextrose 5% premix presentation is not protected by the original ciprofloxacin compound patent.
- Packaging, container, manufacturing, or stability patents may exist at the supplier level, but they do not prevent generic market entry as a category.
- Any relevant formulation or container patent would need to be assessed against the specific NDC and manufacturer.
FDA’s Orange Book is the primary source for patents and exclusivity associated with approved drug products. Mature generic ciprofloxacin injection products do not depend on a live Orange Book patent barrier for commercial protection. [3]
How strong is the patent estate?
The patent estate is weak from a market-exclusivity perspective.
| Patent category |
Commercial status |
| Ciprofloxacin compound patent |
Expired |
| Original branded formulation protection |
Expired or commercially obsolete |
| Method-of-use patents |
No material barrier for ordinary labeled use |
| Container or manufacturing patents |
Potentially supplier-specific and narrow |
| Orange Book protection |
No meaningful barrier to routine generic entry |
| Patent litigation risk |
Low compared with patented specialty products |
The remaining defensibility of the product comes from manufacturing know-how, sterile-facility access, supply contracts, regulatory history, and hospital purchasing relationships.
When does ciprofloxacin injection lose exclusivity?
Ciprofloxacin injection lost meaningful brand exclusivity years ago. The product is already in the mature generic phase.
There is no commercially relevant future loss-of-exclusivity event comparable to a branded drug approaching patent expiry. Generic competition is already established, and any further entrant would compete against existing ANDA holders rather than open a new market.
Paragraph IV challenge risk
Paragraph IV litigation risk is low for the basic product because the core patents have expired. A new ANDA applicant would not normally need to challenge a current composition-of-matter patent to enter the market.
Potential disputes could still arise over:
- A supplier-specific formulation patent
- Container technology
- Manufacturing processes
- Labeling or method-of-use claims
- Regulatory exclusivity associated with a newly approved indication
Those issues would be narrower than a conventional branded-drug patent challenge and would not ordinarily protect the overall ciprofloxacin injection market.
What formulation patents protect the 5% dextrose plastic container?
The commercial product has three technical elements:
- Ciprofloxacin hydrochloride as the active pharmaceutical ingredient
- Dextrose 5% as the infusion vehicle
- A flexible plastic container compatible with the drug and storage conditions
The commercial value of the container lies in compatibility, stability, extractables and leachables control, oxygen and moisture management, port design, terminal sterilization or aseptic processing, and shelf-life validation.
These characteristics can create manufacturing barriers without creating broad market exclusivity. A competitor can enter with a different qualified container or validated manufacturing process if it satisfies FDA requirements.
Manufacturing and intellectual-property barriers
| Barrier |
Strength |
| Sterile injectable manufacturing capacity |
High |
| Validated ciprofloxacin-dextrose stability data |
Moderate |
| Container compatibility testing |
Moderate |
| Drug substance access |
Low |
| Compound patent protection |
None |
| Hospital supply qualification |
Moderate |
| Proprietary formulation exclusivity |
Low at category level |
Sterile injectable production is the most important practical barrier. FDA compliance failures, particulate contamination, fill-finish capacity, and quality-system problems can remove suppliers from the market even when the product has no patent protection.
What is the financial trajectory for ciprofloxacin in dextrose 5%?
The financial trajectory is typical of a mature hospital generic:
- Long-term unit growth is limited.
- Average selling prices are pressured by multisource competition.
- Margins can improve temporarily during shortages.
- Revenue can fall sharply when a supplier loses a hospital contract or discontinues an NDC.
- Premixed presentations can command a modest operational premium over products requiring pharmacy preparation.
- Product-level profitability depends heavily on manufacturing scale and plant utilization.
Public company filings do not generally disclose revenue for this specific formulation. Pfizer, Fresenius Kabi, and other suppliers report at much broader portfolio levels. As a result, product-specific revenue, gross margin, and market share cannot be derived reliably from public annual reports. [4, 5]
Financial exposure by market condition
| Market condition |
Expected effect |
| Stable supply with several suppliers |
Lower prices and compressed margins |
| One major supplier exits |
Higher prices and increased share for remaining suppliers |
| Ciprofloxacin shortage |
Short-term revenue and price uplift |
| Greater fluoroquinolone restriction |
Lower demand |
| Increased use of ready-to-administer products |
Supports premix volumes |
| Hospital budget pressure |
Favors low-cost suppliers |
| Manufacturing deviation |
Can produce lost sales and contract penalties |
The product is therefore a low-growth, execution-sensitive asset. Its value is greater as part of a hospital injectable portfolio than as a standalone branded franchise.
What is the Orange Book status of ciprofloxacin injection?
The Orange Book framework confirms that ciprofloxacin injection is an established multisource product with no current branded exclusivity comparable to a newly approved drug. The relevant analysis should distinguish:
- The original NDA for the branded product
- ANDAs for generic ciprofloxacin injection
- Individual NDCs for specific container sizes
- Whether a product is currently marketed or listed as discontinued
- Any patents or exclusivities linked to a particular approved label
Orange Book status does not by itself establish current commercial availability. DailyMed, FDA labeling, manufacturer catalogs, and the FDA Drug Shortages database are needed to assess whether a listed product is actively supplied. [3, 6]
What litigation and settlement agreements affect ciprofloxacin injection?
The basic ciprofloxacin injection category has low current patent-litigation exposure because the principal exclusivity period ended long ago. There is no clear commercial basis for expecting a new wave of branded-generic settlement activity around the core product.
Any active dispute would more likely involve:
- Product liability
- Manufacturing quality
- Contract supply
- Antitrust or procurement conduct
- Labeling and safety disclosures
- A narrow container or process patent
These disputes would affect individual suppliers rather than the entire category.
What generic launch scenarios exist?
Base case: stable multisource supply
Several suppliers remain active, hospital demand remains steady, and price competition continues. Revenue is flat to modestly lower, while margins remain dependent on procurement contracts and production efficiency.
Upside case: supplier consolidation or shortage
A plant closure, quality recall, or manufacturing interruption reduces supply. Remaining manufacturers gain volume and may obtain temporary pricing power. The effect is usually strongest for specific strengths or container sizes.
Downside case: clinical substitution
Hospitals reduce fluoroquinolone use because of resistance, safety concerns, or stewardship initiatives. Ceftriaxone, cefepime, piperacillin/tazobactam, carbapenems, and oral step-down therapy absorb part of the demand.
Portfolio case: premix conversion
Hospitals move from compounded bags to ready-to-use products to reduce pharmacy labor and medication-preparation risk. This can support the dextrose-container segment even if total ciprofloxacin use remains flat.
How does ciprofloxacin injection compare with newer antibiotics?
Ciprofloxacin injection has a weaker commercial profile than newer branded or specialty antibiotics because it lacks patent protection and has extensive generic competition. It has a stronger supply-chain position than many low-volume sterile injectables because ciprofloxacin is a recognized hospital antibiotic with established demand.
| Attribute |
Ciprofloxacin in D5W |
New branded antibiotic |
| Patent protection |
Minimal or none |
Often substantial |
| Generic competition |
High |
Low before loss of exclusivity |
| Pricing power |
Low |
Higher |
| Hospital demand |
Established |
Depends on resistance and formulary adoption |
| Regulatory risk |
Safety warnings and resistance |
Clinical and reimbursement risk |
| Revenue visibility |
Moderate at category level |
Often higher during exclusivity |
| Manufacturing risk |
High for sterile supply |
High, but offset by margin |
Key Takeaways
- Ciprofloxacin in dextrose 5% plastic containers is a mature generic hospital injectable.
- The category has no meaningful current compound-patent or branded-exclusivity protection.
- Biosimilar risk does not apply because ciprofloxacin is a small-molecule drug.
- Generic competition, hospital tenders, and sterile-manufacturing capacity determine commercial performance.
- Premixed packaging provides operational value by reducing pharmacy compounding requirements.
- Long-term unit growth is limited by antimicrobial stewardship, resistance, fluoroquinolone safety concerns, and alternative intravenous antibiotics.
- Revenue is not publicly disclosed at the individual product level.
- The most material upside scenario is a supply disruption affecting competing suppliers.
- The primary barriers are manufacturing quality, regulatory compliance, supply reliability, and hospital contracting rather than patents.
FAQs
Is ciprofloxacin in dextrose 5% still under patent?
No meaningful original ciprofloxacin patent protection remains. Any relevant current rights would likely be narrow patents covering a specific process, container, or supplier formulation.
Is ciprofloxacin in D5W a biosimilar?
No. Ciprofloxacin is a chemically synthesized small-molecule drug. Generic versions are approved through the ANDA framework rather than the biosimilar pathway.
Can a new generic launch ciprofloxacin in a plastic container?
Yes, subject to FDA approval, applicable pharmaceutical-equivalence requirements, container compatibility, stability data, manufacturing controls, and commercial supply capability.
Why can a generic ciprofloxacin injection experience price increases?
Sterile injectable supply is vulnerable to plant shutdowns, quality findings, recalls, shortages of components, and supplier exits. A reduction in the number of active manufacturers can increase prices even without patent protection.
Which products most directly replace ciprofloxacin injection in hospitals?
The closest clinical alternatives include levofloxacin, ceftriaxone, cefepime, piperacillin/tazobactam, carbapenems, and oral ciprofloxacin when intravenous treatment is no longer necessary.
References
-
U.S. Food and Drug Administration. (2024). Ciprofloxacin injection prescribing information. FDA/DailyMed labeling.
-
U.S. Food and Drug Administration. (2018). FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
-
Pfizer Inc. (2024). 2023 annual report. Pfizer Investor Relations.
-
Fresenius SE & Co. KGaA. (2024). 2023 annual report. Fresenius Investor Relations.
-
U.S. Food and Drug Administration. (2024). FDA drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
